SCHEMBL23210723

SCHEMBL23210723

COc1cc2c(cnn2C(=O)O)nc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHMT2 P34897 2/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 2/20 0.41
GAA P10253 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
HSP90AB1 P08238 1/20 0.36
EGLN1 Q9GZT9 2/20 0.36
PGK1 P00558 3/20 0.35
ALDH1A1 P00352 4/20 0.35
MAPT P10636 2/20 0.35
POLB P06746 1/20 0.35
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
KDM4E B2RXH2 3/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
ALOX15 P16050 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23210861 0.83 SHMT2 (0.38) SHMT2RAB9ANPC1GAACASP3
SCHEMBL29907085 0.83 SHMT2 (0.38) SHMT2RAB9ANPC1GAACASP3
SCHEMBL23236541 0.77 PGK1 (0.39) SHMT2RAB9ANPC1GAACASP3
SCHEMBL33525846 0.77 PGK1 (0.39) SHMT2RAB9ANPC1GAACASP3
SCHEMBL18578596 0.72 HSP90AB1 (0.41) SHMT2RAB9ANPC1GAACASP3
SCHEMBL23210776 0.72 MTNR1A (0.36) SHMT2RAB9ANPC1GAACASP3
SCHEMBL30621458 0.72 ALDH1A1 (0.39) SHMT2RAB9ANPC1ALDH1A1MTNR1A
SCHEMBL29907196 0.70 FGFR1 (0.35) NPC1GAAPGK1ALDH1A1MAPT
SCHEMBL23211069 0.70 FGFR1 (0.35) NPC1GAAPGK1ALDH1A1MAPT
SCHEMBL23210848 0.70 NPC1 (0.41) RAB9ANPC1GAAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 US disclosed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 EP disclosed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 WO disclosed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 SHMT2 1585/4885RAB9A 3393/4885NPC1 3370/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 SHMT2 1585/4885RAB9A 3393/4885NPC1 3370/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 SHMT2 1585/4885RAB9A 3393/4885NPC1 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.